DrugBank 5.0: a major update to the DrugBank database for 2018
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
DrugBank (www.drugbank.ca) is a web-enabled database containing comprehensive molecular information about drugs, their mechanisms, their interactions and their targets. First described in 2006, DrugBank has continued to evolve over the past 12 years in response to marked improvements to web standards and changing needs for drug research and development. This year's update, DrugBank 5.0, represents the most significant upgrade to the database in more than 10 years. In many cases, existing data content has grown by 100% or more over the last update. For instance, the total number of investigational drugs in the database has grown by almost 300%, the number of drug-drug interactions has grown by nearly 600% and the number of SNP-associated drug effects has grown more than 3000%. Significant improvements have been made to the quantity, quality and consistency of drug indications, drug binding data as well as drug-drug and drug-food interactions. A great deal of brand new data have also been added to DrugBank 5.0. This includes information on the influence of hundreds of drugs on metabolite levels (pharmacometabolomics), gene expression levels (pharmacotranscriptomics) and protein expression levels (pharmacoprotoemics). New data have also been added on the status of hundreds of new drug clinical trials and existing drug repurposing trials. Many other important improvements in the content, interface and performance of the DrugBank website have been made and these should greatly enhance its ease of use, utility and potential applications in many areas of pharmacological research, pharmaceutical science and drug education.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“DrugBank primarily contains drug indications extracted from drug labels, while MEDI utilizes public internet sources to drug indications, and is a well utilized resource of drug indications.”
From OnSIDES database: Extracting adverse drug events from drug labels using natural language processing models (2025) · cites this paper as [48]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Finally, we searched DrugBank84 to identify therapeutic compounds targeting AD-associated proteins. Of the 38 proteins, 15 had reported molecules (Fig. 4D).”
From Proteogenomic analysis of human cerebrospinal fluid identifies neurologically relevant regulation and implicates causal proteins for Alzheimer’s disease (2024) · cites this paper as [84]
In the citing paper
“AVPR2 and NPR1 genes play pivotal roles in regulating fluid and electrolyte balance via complementary but distinct pathways. AVPR2 contributes to water retention and urine concentration, whereas NPR1 facilitates vasodilatation, lowers blood pressure and enhances water excretion47.”
From A foundation model for clinician-centered drug repurposing (2024) · cites this paper as [47]
In the citing paper
“In essence, the CC is an alternative representation of the small-molecule knowledge deposited in the public domain and, as such, it is also limited by the availability of experimental data and the coverage of its source databases (e.g., ChEMBL9 or DrugBank10).”
From Bioactivity descriptors for uncharacterized chemical compounds (2021) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DrugBank: a comprehensive resource for in silico drug discovery and exploration
Wishart, D. S. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj067 · Cited by 3,892 · cited 1×
“DrugBank 1.0, released in 2006, provided novel (at the time) physico-chemical data on selected FDA-approved drugs and their drug-targets (2).”
BackgroundInfluentialSelf-citationDrugBank: a knowledgebase for drugs, drug actions and drug targets
Wishart, D. S., Knox, C., Guo, A. C., Cheng, D., Shrivastava, S., Tzur, D., Gautam, B., & Hassanali, M. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkm958 · Cited by 2,861 · cited 1×
“DrugBank 2.0, released in 2008, added pharmacological, pharmacogenomic and molecular biological data (3).”
BackgroundInfluentialSelf-citationThe new NHGRI-EBI Catalog of published genome-wide association studies (GWAS Catalog)
MacArthur, J., Bowler, E., Cerezo, M., Gil, L., Hall, P., Hastings, E., Junkins, H., McMahon, A., Milano, A., Morales, J., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1133 · Cited by 2,161 · cited 2×
“org and FDA labels), as well as material collated from sources such as The Human Cytochrome P450 (CYP) Allele Nomenclature Database (12) and the NHGRI-EBI GWAS Catalog (13).”
BackgroundDrugBank 4.0: shedding new light on drug metabolism
Law, V., Knox, C., Djoumbou, Y., Jewison, T., Guo, A. C., Liu, Y., Maciejewski, A., Arndt, D., Wilson, M., Neveu, V., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1068 · Cited by 1,993 · cited 1×
“tion, distribution, metabolism, excretion and toxicity) data (5).”
Self-citationDrugBank 3.0: a comprehensive resource for 'Omics' research on drugs
Knox, C., Law, V., Jewison, T., Liu, P., Ly, S., Frolkis, A., Pon, A., Banco, K., Mak, C., Neveu, V., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq1126 · Cited by 1,831 · cited 1×
“DrugBank 3.0, released in 2010, added drug–drug and drug–food interactions, drug transporter data as well as pharmacokinetic information (4).”
BackgroundInfluentialSelf-citationClassyFire: automated chemical classification with a comprehensive, computable taxonomy
Djoumbou Feunang, Y., Eisner, R., Knox, C., Chepelev, L., Hastings, J., Owen, G., Fahy, E., Steinbeck, C., Subramanian, S., Bolton, E., et al. (2016) · Journal of Cheminformatics · doi:10.1186/s13321-016-0174-y · Cited by 1,525
Self-citationThe Comparative Toxicogenomics Database: update 2017
Davis, A. P., Grondin, C. J., Johnson, R. J., Sciaky, D., King, B. L., McMorran, R., Wiegers, J., Wiegers, T. C., & Mattingly, C. J. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw838 · Cited by 544 · cited 1×
“Additional pharmacoproteomic and pharmacotranscriptomic data were obtained from the CTD (18).”
MethodPredicting drug metabolism: experiment and/or computation?
Kirchmair, J., Göller, A. H., Lang, D., Kunze, J., Testa, B., Wilson, I. D., Glen, R. C., & Schneider, G. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4581 · Cited by 502 · cited 1×
“It has also become much more robust and sophisticated (21).”
BackgroundAllen, F., Pon, A., Wilson, M., Greiner, R., & Wishart, D. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku436 · Cited by 464 · cited 7×
“In particular, CFM-ID (19) and CFM-ID 2.”
BackgroundInfluentialSelf-citationSim, S. C., & Ingelman-Sundberg, M. (2010) · Human Genomics · doi:10.1186/1479-7364-4-4-278 · Cited by 216 · cited 2×
“org and FDA labels), as well as material collated from sources such as The Human Cytochrome P450 (CYP) Allele Nomenclature Database (12) and the NHGRI-EBI GWAS Catalog (13).”
Background
Cited by
Items 501–600 of 1,056
Li, R., Guo, C., Li, Y., Qin, Z., & Huang, W. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa079 · Cited by 95
“Using the Traditional Chinese Medicine Systems Pharmacology (TCMSP) [17], Drugbank [18], SuperPred [19] and Swiss Target Prediction [20] databases, well-reported pharmacological targets of VC were obtained.”
MethodInformatics for Chemistry, Biology, and Biomedical Sciences
López‐López, E., Bajorath, J., & Medina‐Franco, J. L. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c01301 · Cited by 87
Graph2MDA: a multi-modal variational graph embedding model for predicting microbe–drug associations
Deng, L., Huang, Y., Liu, X., & Liu, H. (2021) · Bioinformatics · doi:10.1093/bioinformatics/btab792 · Cited by 105
Mahmoud, A., Mostafa, A., Al-Karmalawy, A. A., Zidan, A. M., Abulkhair, H. S., Mahmoud, S. H., Shehata, M., ElHefnawi, M., & Ali, M. A. (2021) · Heliyon · doi:10.1016/j.heliyon.2021.e07962 · Cited by 88
“A total of 16 DAAs, covering three DAA classes (eight NS3/4A, six NS5A, and two NS5B inhibitors) were collected from the literature and DrugBank [38, 39].”
From genetic associations to genes: methods, applications, and challenges
Qi, T., Song, L., Guo, Y., Chen, C., & Yang, J. (2024) · Trends in Genetics · doi:10.1016/j.tig.2024.04.008 · Cited by 105
Systems biology based drug repositioning for development of cancer therapy
Turanlı, B., Altay, Ö., Borén, J., Türkez, H., Nielsen, J., Uhlén, M., Arğa, K. Y., & Mardinoğlu, A. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.09.020 · Cited by 92
The 2018 Nucleic Acids Research database issue and the online molecular biology database collection
Rigden, D. J., & Fernández, X. M. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx1235 · Cited by 94
“Update papers from the IUPHAR/BPS Guide to Pharmacology and DrugBank are highlights of the drug and drug target section while a number of proteomics databases including proteomicsDB are also covered.”
BackgroundInfluentialImprovement of Prediction Performance With Conjoint Molecular Fingerprint in Deep Learning
Xie, L., Xu, L., Kong, R., Chang, S., & Xu, X. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.606668 · Cited by 91
“…the generalizability of the proposed conjoint fingerprint, we conducted the regression task on three tasks: predicting logP of DrugBank database (Wishart et al., 2018), predicting logP of the Lipophilicity dataset that is collected in the MoleculeNet (Wu et al., 2018), and predicting binding…”
MethodHINT: Hierarchical interaction network for clinical-trial-outcome predictions
Fu, T., Huang, K., Xiao, C., Glass, L. M., & Sun, J. (2022) · Patterns · doi:10.1016/j.patter.2022.100445 · Cited by 135
“ca/) contains the biochemical description of many drugs, which allows for the computational modeling of drug molecules.(6) Over the years, there have been early attempts to predict individual components in clinical trials to improve the trial results, including using electroencephalographic (EEG)measures to predict th…”
BackgroundZhu, W. T., Li, Y., Zhao, J., Wang, Y., Li, Y., & Wang, Y. (2022) · Annals of Medicine · doi:10.1080/07853890.2022.2034931 · Cited by 90
“ca) to find drug targets for approved intervention CTD-ILD [23].”
BackgroundUnderstanding Failure and Improving Treatment Using HDAC Inhibitors for Prostate Cancer
Rana, Z., Diermeier, S. D., Hanif, M., & Rosengren, R. J. (2020) · Biomedicines · doi:10.3390/biomedicines8020022 · Cited by 89
The CSD Drug Subset: The Changing Chemistry and Crystallography of Small Molecule Pharmaceuticals
Bryant, M. J., Black, S. N., Blade, H., Docherty, R., Maloney, A. G. P., & Taylor, S. C. (2019) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2018.12.011 · Cited by 83
Druggable genome and precision medicine in cancer: current challenges
Dupont, C., Riegel, K., Pompaiah, M., Juhl, H. H., & Rajalingam, K. (2021) · FEBS Journal · doi:10.1111/febs.15788 · Cited by 86
Kuwahara, H., & Gao, X. (2021) · Journal of Cheminformatics · doi:10.1186/s13321-021-00506-2 · Cited by 97
Kotlyar, M., Pastrello, C., Ahmed, Z., Chee, J., Varyova, Z., & Jurisica, I. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkab1034 · Cited by 80
“PPIs are annotated with drug target class information from UniProt (45) 2021 03, and targeting drugs from DrugBank (57) v5.”
Wang, J., Wu, M., Huang, X., Wang, L., Zhang, S., Liu, H., & Zheng, J. (2022) · Database · doi:10.1093/database/baac030 · Cited by 91
Prediction of drug-drug interaction events using graph neural networks based feature extraction
Al-Rabeah, M. H., & Lakizadeh, A. (2022) · Scientific Reports · doi:10.1038/s41598-022-19999-4 · Cited by 100
“But the rest of the matrices were collected from the DrugBank database.”
MethodInfluentialIs depression the missing link between inflammatory mediators and cancer?
Polityńska, B., Pokorska, O., Wojtukiewicz, A. M., Sawicka, M., Mysliwiec, M., Honn, K. V., Tucker, S. C., & Wojtukiewicz, M. Z. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108293 · Cited by 89
Challenges in natural product-based drug discovery assisted with in silico -based methods
Simoben, C. V., Babiaka, S. B., Moumbock, A. F. A., Namba-Nzanguim, C. T., Eni, D. B., Medina‐Franco, J. L., Günther, S., Ntie‐Kang, F., & Sippl, W. (2023) · RSC Advances · doi:10.1039/d3ra06831e · Cited by 87
Chakraborty, C., Bhattacharya, M., Lee, S., Wen, Z., & Lo, Y.-H. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102295 · Cited by 100
Zhao, J., Lv, C., Wu, Q., Zeng, H., Guo, X., Yang, J., Tian, S., & Zhang, W. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104365 · Cited by 90
Extending the Nested Model for User-Centric XAI: A Design Study on GNN-based Drug Repurposing
Wang, Q., Huang, K., Chandak, P., Zitnik, M., & Gehlenborg, N. (2023) · IEEE Transactions on Visualization and Computer Graphics · doi:10.1109/tvcg.2022.3209435 · Cited by 82
Kops, C. D. B., Stork, C., Šícho, M., Kochev, N. T., Svozil, D., Jeliazkova, N., & Kirchmair, J. (2019) · Frontiers in Chemistry · doi:10.3389/fchem.2019.00402 · Cited by 82
AGCN: Attention-based graph convolutional networks for drug-drug interaction extraction
Park, C., Park, J., & Park, S. (2020) · Expert Systems with Applications · doi:10.1016/j.eswa.2020.113538 · Cited by 89
“The characteristics of the approaches are as follows: UTurku (Björne et al., 2013) uses features from dependency parsing and domain resources such as DrugBank.”
BackgroundInfluentialTherapeutic promises of ginkgolide A: A literature-based review
Sarkar, C. K., Quispe, C., Jamaddar, S., Hossain, R., Ray, P., Mondal, M., Mohamed, Z. A., Mohammed, J. S., Salehi, B., Islam, M. T., et al. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110908 · Cited by 89
Zhang, Y., Yao, Q., Yue, L., Wu, X., Zhang, Z., Lin, Z., & Zheng, Y. (2023) · Nature Computational Science · doi:10.1038/s43588-023-00558-4 · Cited by 105
“6,13, we used two benchmark datasets, DrugBank 22 and TWOSIDES 23 , as the interaction network 𝒩𝒩 D (Supplementary Table 1).”
A Perspective on Foundation Models in Chemistry
Choi, J., Nam, G., Choi, J., & Jung, Y. (2025) · JACS Au · doi:10.1021/jacsau.4c01160 · Cited by 107
Gu, S., Xue, Y., Gao, Y., Shen, S., Zhang, Y., Chen, K., Xue, S., Ji, P., Tang, Y., Zhu, H., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-71030-w · Cited by 87
Banerjee, P., & Preißner, R. (2018) · Frontiers in Chemistry · doi:10.3389/fchem.2018.00093 · Cited by 86
“A total of 1,925 approved small molecule drugs were collected from DrugBank database (Wishart et al., 2017).”
BackgroundMethodInfluentialPrediction of drug adverse events using deep learning in pharmaceutical discovery
Lee, C. Y., & Chen, Y. P. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa040 · Cited by 86
Johnson, K.-A., Muzzin, N., Toufanian, S., Slick, R. A., Lawlor, M. W., Seifried, B., Moquin, P., Latulippe, D. R., & Hoare, T. R. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2020.06.006 · Cited by 83
Prediction of drug-target interactions based on multi-layer network representation learning
Shang, Y., Gao, L., Zou, Q., & Yu, L. (2020) · Neurocomputing · doi:10.1016/j.neucom.2020.12.068 · Cited by 85
How can natural language processing help model informed drug development?: a review
Bhatnagar, R., Sardar, S., Beheshti, M., & Podichetty, J. T. (2022) · JAMIA Open · doi:10.1093/jamiaopen/ooac043 · Cited by 88
In Silico Repurposed Drugs against Monkeypox Virus
Lam, H. Y. I., Guan, J. S., & Mu, Y. (2022) · Molecules · doi:10.3390/molecules27165277 · Cited by 84
“54 11 h [38] Hyponatremia, congestive heart failure [36]”
BackgroundMethodInfluentialApplication of machine learning techniques to the analysis and prediction of drug pharmacokinetics
Ota, R., & Yamashita, F. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.11.014 · Cited by 90
Metabolic and proteomic signatures of type 2 diabetes subtypes in an Arab population
Zaghlool, S. B., Halama, A., Stephan, N., Gudmundsdottir, V., Gudnason, V., Jennings, L. L., Thangam, M., Ahlqvist, E., Malik, R. A., Albagha, O. M. E., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34754-z · Cited by 79
Metapath-aggregated heterogeneous graph neural network for drug–target interaction prediction
Li, M., Cai, X., Xu, S., & Ji, H. (2023) · Briefings in Bioinformatics · doi:10.1093/bib/bbac578 · Cited by 88
Understanding Membrane Protein Drug Targets in Computational Perspective
Gong, J., Chen, Y., Pu, F., Sun, P., He, F., Zhang, L., Li, Y., Ma, Z., & Wang, H. (2018) · Current Drug Targets · doi:10.2174/1389450120666181204164721 · Cited by 87
Drug repositioning through integration of prior knowledge and projections of drugs and diseases
Xuan, P., Cao, Y., Zhang, T., Wang, X., Pan, S., & Shen, T. (2019) · Bioinformatics · doi:10.1093/bioinformatics/btz182 · Cited by 83
Prediction of adverse drug reactions based on knowledge graph embedding
Zhang, F., Sun, B., Diao, X., Zhao, W., & Shu, T. (2021) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-021-01402-3 · Cited by 92
Yang, Y. R., Gao, D., Xie, X., Qin, J., Li, J., Lin, H., Yan, D., & Deng, K. (2022) · Clinical Pharmacokinetics · doi:10.1007/s40262-022-01180-9 · Cited by 85
ADCdb: the database of antibody–drug conjugates
Shen, L., Sun, X., Chen, Z., Guo, Y., Shen, Z., Song, Y., Xin, W., Ding, H., Ma, X., Xu, W., et al. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad831 · Cited by 88
“…collection of biological / chemical information, such as Drugs@FDA ( 5 ), NCATS Inxights Drugs ( 6 ), DrugMAP ( 7 ), ChEMBL ( 8 ), DrugBank ( 9 ) and so on; some others aim at describing the particular components of each ADC, which include (a) those offering mAb moiety, such as: IMGT /…”
BackgroundContextual AI models for single-cell protein biology
Li, M. M., Huang, Y., Sumathipala, M. G., Liang, M. Q., Valdeolivas, A., Ananthakrishnan, A. N., Liao, K. P., Marbach, D., & Žitnik, M. (2024) · Nature Methods · doi:10.1038/s41592-024-02341-3 · Cited by 99
“Balsalazide and mesalamine are aminosalicylate drugs (disease-modifying antirheumatic drugs) commonly used to treat ulcerative colitis by targeting peroxisome proliferator-activated receptor gamma (PPARG) 61,79 .”
FusionGDB: fusion gene annotation DataBase
Kim, P., & Zhou, X. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky1067 · Cited by 82
Gojo, J., Pavelka, Z., Zapletalová, D., Schmook, M. T., Mayr, L., Madlener, S., Kýr, M., Vejmělková, K., Smrčka, M., Czech, T., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01436 · Cited by 83
“Respective treatment approaches were suggested according to previously described target actionability described in the INFORM trial (42), FDA datasheets, and Drugbank Canada (35), at mycancergenome.”
BackgroundMethodInfluentialStatin therapy and risk of Alzheimer's and age‐related neurodegenerative diseases
Torrandell‐Haro, G., Branigan, G. L., Vitali, F., Geifman, N., Zissimopoulos, J. M., & Brinton, R. D. (2020) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12108 · Cited by 79
Fan, K., Cheng, L., & Li, L. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab271 · Cited by 84
Dockey: a modern integrated tool for large-scale molecular docking and virtual screening
Du, L., Geng, C., Zeng, Q., Huang, T. L., Tang, J., Chu, Y., & Zhao, K. (2023) · Briefings in Bioinformatics · doi:10.1093/bib/bbad047 · Cited by 87
Zhao, B.-W., Su, X., Yang, Y., Li, D., Li, G., Hu, P., Luo, X., & Hu, L. (2024) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2024.06.032 · Cited by 86
Deep learning of pharmacogenomics resources: moving towards precision oncology
Chiu, Y.-C., Chen, H.-I. H., Gorthi, A., Mostavi, M., Zheng, S., Huang, Y., & Chen, Y. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbz144 · Cited by 78
“…databases focus on the targeted gene variants and proteins,such as PharmGKB (Pharmacogenetics Knowledge Base) [117], Cancer Therapeutics Response Portal (CTRP) [118–120], DrugBank [94], Therapeutic Target Database (TTD) [94], Search Tool for Interacting Chemicals (STITCH) [121] and OncoKB [122].”
BackgroundMethodMedvedev, K. E., Kinch, L. N., Schaeffer, R. D., & Grishin, N. V. (2019) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1007569 · Cited by 73
“DrugBank [79] contains one target of methotrexate with confirmed pharmacological action: human dihydrofolate reductase (DHFR, UniProt ID: P00374, EC: 1.”
BackgroundAntimicrobial Agents and Urinary Tract Infections
Issakhanian, L., & Behzadi, P. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825999190619130216 · Cited by 84
Zebrafish xenografts as a fast screening platform for bevacizumab cancer therapy
de Almeida, C. R., Mendes, R. V., Pezzarossa, A., Gago, J., Carvalho, C. T., Alves, A., Nunes, V. M., Brito, M. J., Cardoso, M. J., Ribeiro, J. M., et al. (2020) · Communications Biology · doi:10.1038/s42003-020-1015-0 · Cited by 78
Chemoinformatics-based enumeration of chemical libraries: a tutorial
Saldívar‐González, F. I., Huerta-García, C. S., & Medina‐Franco, J. L. (2020) · Journal of Cheminformatics · doi:10.1186/s13321-020-00466-z · Cited by 88
“Figure 6a illustrates an application of PCA to generate a visual representation of the property-based chemical space of 24,698 lactams,7884 bis-heterocycles, 649 isoindolinones, and a collection of 2125 drugs approved for clinical use obtained from DrugBank [117].”
MethodSAveRUNNER: an R-based tool for drug repurposing
Fiscon, G., & Paci, P. (2021) · BMC Bioinformatics · doi:10.1186/s12859-021-04076-w · Cited by 81
Nakata, M., & Maeda, T. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.3c00899 · Cited by 97
Santana-Codina, N., Chandhoke, A. S., Yu, Q., Małachowska, B., Kuljanin, M., Gikandi, A., Stańczak, M., Gableske, S., Jedrychowski, M. P., Scott, D. A., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.03.021 · Cited by 77
VARIDT 1.0: variability of drug transporter database
Yin, J., Sun, W. C., Li, F., Hong, J., Li, X., Zhou, Y., Lu, Y., Liu, M., Zhang, X. Z., Chen, N., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz878 · Cited by 77
“Some of these databases (including UniProt (22), PDB (23), KEGG (24), ChEMBL (25), DrugBank (26) and TTD (27)) contain transporter information as part of a broader collection of biological and pharmacological data, and some others (including TCDB (28), TransportDB (29), HMPAS (30) and METscout (31)) include general cl…”
BackgroundGuillén‐Guío, B., Lorenzo-Salazar, J. M., Ma, S., Hou, P., Hernández-Beeftink, T., Corrales, A., García-Laorden, M. I., Jou, J., Espinosa, E., Muriel, A., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30368-6 · Cited by 82
Storey, K. M., Lawler, S. E., & Jackson, T. L. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00151 · Cited by 78
TeroKit: A Database-Driven Web Server for Terpenome Research
Zeng, T., Liu, Z., Zhuang, J., Jiang, Y., He, W., Diao, H., Lv, N., Jian, Y., Liang, D., Qiu, Y., et al. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00141 · Cited by 78
Predicting novel drugs for SARS-CoV-2 using machine learning from a >10 million chemical space
Kowalewski, J., & Ray, A. (2020) · Heliyon · doi:10.1016/j.heliyon.2020.e04639 · Cited by 76
“Accordingly, we used the machine learning models to predict activities of ~100,000 FDA registered chemicals (UNII database) [19] as well as the DrugBank [20] and Therapeutic Targets [21, 22] databases, which include information on drug interactions, pathways, and approval status.”
MethodAn overview of graph databases and their applications in the biomedical domain
Reina, S. T., Rincón, M., & Martínez‐Tomás, R. (2021) · Database · doi:10.1093/database/baab026 · Cited by 83
“Lastly, it finds the drugs, extracted from DrugBank (130), which target genes and treats or contraindicate the disease.”
BackgroundAhmad, S., Singh, V. P., Gautam, H. K., & Raza, K. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2209673 · Cited by 86
“Further, the study was extended to the molecular interaction fingerprinting, ADMET, and optimisation of the compound and then performed the molecular dynamics simulation to understand the compound’s stability with each protein.”
BackgroundInfluentialLiu, J., Guan, S., Zou, Q., Wu, H., Tiwari, P., & Ding, Y. (2023) · Knowledge-Based Systems · doi:10.1016/j.knosys.2023.111329 · Cited by 83
Koirala, M., Yan, L., Mohamed, Z., & DiPaola, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199384 · Cited by 92
“Pharmacokinetic and toxicity data for approved drugs, useful for validation and model tuning [130].”
Omolo, C. A., Kalhapure, R. S., Agrawal, N., Rambharose, S., Mocktar, C., & Govender, T. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00505 · Cited by 81
The virtuous cycle of human genetics and mouse models in drug discovery
Nadeau, J. H., & Auwerx, J. H. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0009-9 · Cited by 84
Recent advances in AI-based toxicity prediction for drug discovery
Lee, H., Kim, J., Kim, J.-W., & Lee, Y. (2025) · Frontiers in Chemistry · doi:10.3389/fchem.2025.1632046 · Cited by 76
Shi, J., Mao, K.-T., Yu, H., & Yiu, S. (2019) · Journal of Cheminformatics · doi:10.1186/s13321-019-0352-9 · Cited by 81
A Multi-Omics Interpretable Machine Learning Model Reveals Modes of Action of Small Molecules
Patel-Murray, N. L., Adam, M., Huynh, N. C., Wassie, B. T., Milani, P., & Fraenkel, E. (2020) · Scientific Reports · doi:10.1038/s41598-020-57691-7 · Cited by 81
“Cyproheptadine and meclizine are both antihistamines known to antagonize the histamine H1 receptor 29 .”
BackgroundIn vitro and in vivo identification of clinically approved drugs that modify ACE2 expression
Sinha, S., Cheng, K., Schäffer, A. A., Aldape, K., Schiff, E., & Ruppin, E. (2020) · Molecular Systems Biology · doi:10.15252/msb.20209628 · Cited by 76
“Specifically, we downloaded an SQL database of GEO metadata (timestamp: May 10, 2020) using the R package GEOmetadb (Zhu et al , 2008) and used an in-house script (see Data availability) to query the metadata for GEO datasets and data series whose summary, description, or study design information contain the generic n…”
InfluentialApplications of Machine Learning in Solid Oral Dosage Form Development
Lou, H., Lian, B., & Hageman, M. J. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2021.04.013 · Cited by 84
Compound–protein interaction prediction by deep learning: Databases, descriptors and models
Du, B.-X., Qin, Y., Jiang, Y.-F., Xu, Y., Yiu, S.-M., Yu, H., & Shi, J.-Y. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.02.023 · Cited by 73
Identification of circadian clock modulators from existing drugs
Tamai, K., Nakane, Y., Ota, W., Kobayashi, A., Ishiguro, M., Kadofusa, N., Ikegami, K., Yagita, K., Shigeyoshi, Y., Sudo, M., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201708724 · Cited by 79
“According to the DrugBank database (version 5.0.11 released 2017-12-20: www.drugbank.ca) ( Wishart et al , 2018), there have been at least 12 targets of DHEA reported in humans (Table EV1).”
InfluentialTsuji, S., Hase, T., Yachie-Kinoshita, A., Nishino, T., Ghosh, S., Kikuchi, M., Shimokawa, K., Aburatani, H., Kitano, H., & Tanaka, H. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00826-3 · Cited by 75
“324 We obtained information of drugs and that of their target genes from DrugBank 325 database [42] (http://www.”
BackgroundRLDOCK: A New Method for Predicting RNA–Ligand Interactions
Sun, L., Jiang, Y., Zhou, Y., & Chen, S. (2020) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.0c00798 · Cited by 83
Nallusamy, S., Mannu, J., Ravikumar, C. N., Angamuthu, K., Nathan, B., Nachimuthu, K., Gnanam, R., Raveendran, M., Subbarayalu, M., & Neelakandan, K. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.667704 · Cited by 81
“From the DrugBank database, 99 chemical structures of drugs approved for the treatment of respiratory diseases and compounds exhibiting antiviral activity were collected.”
MethodShen, L., Liu, F., Huang, L., Liu, G., Zhou, L., & Peng, L. (2021) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2021.105119 · Cited by 80
“On November 19, 2020, it was authorized for the treatment of COVID-19 in combination with baricitinib [58].”
InfluentialOwen, M. J., Lefebvre, S., Hansen, C., Kunard, C. M., Dimmock, D., Smith, L. D., Scharer, G. H., Mardach, R., Willis, M. J. H., Feigenbaum, A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31446-6 · Cited by 80
Bondarev, A. D., Attwood, M. M., Jonsson, J., Chubarev, V. N., Tarasov, V. V., Liu, W., & Schiöth, H. B. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1057083 · Cited by 80
“These studies were originally based on information from the Drugs in Clinical Trials Database (discontinued) from CenterWatch1 and the DrugBank database (Wishart et al., 2018) and spans from 1983 to 2019.”
MethodFrom ‘Omics to Multi-omics Technologies: the Discovery of Novel Causal Mediators
Mohammadi‐Shemirani, P., Sood, T., & Paré, G. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01078-8 · Cited by 83
Integrated Molecular Modeling and Machine Learning for Drug Design
Xia, S., Chen, E., & Zhang, Y. (2023) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.3c00814 · Cited by 81
Leveraging machine learning models in evaluating ADMET properties for drug discovery and development
Magesh, V., Rao, G. C., Karthik, M. J., & Maddi, S. (2026) · ADMET & DMPK · doi:10.5599/admet.2772 · Cited by 91
Leveraging network pharmacology for drug discovery: Integrative approaches and emerging insights
Li, L., & Kar, S. (2025) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2025.100220 · Cited by 91
Brown, N., Cambruzzi, J., Cox, P. J., Davies, M., Dunbar, J., Plumbley, D., Sellwood, M. A., Sim, A., Williams-Jones, B. I., Zwierzyna, M., et al. (2018) · Progress in medicinal chemistry · doi:10.1016/bs.pmch.2017.12.003 · Cited by 83
CovalentInDB: a comprehensive database facilitating the discovery of covalent inhibitors
Du, H., Gao, J., Weng, G., Ding, J., Chai, X., Pang, J., Kang, Y., Li, D., Cao, D., & Hou, T. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa876 · Cited by 81
“The information in CovalentInDB was collected from scientific literatures and several scientific databases, including PubChem (11), ChEMBL (10), DrugBank (18), PDB (19) and UniProt (20).”
BackgroundZhou, Y., Lih, T. M., Pan, J., Höti, N., Dong, M., Cao, L., Hu, Y., Cho, K.-C., Chen, S., Eguez, R. V., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01013-x · Cited by 86
Fisher, C. M., Croley, T. R., & Knolhoff, A. M. (2021) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2021.116188 · Cited by 76
Goh, W. J., Tan, S. X., Pastorin, G., Ho, P. C., Hu, J., & Lim, S. H. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120360 · Cited by 79
Limited evolution of the actionable metastatic cancer genome under therapeutic pressure
van de Haar, J., Hoes, L. R., Roepman, P., Lolkema, M. P., Verheul, H. M. W., Gelderblom, H. A. J., Langen, A. J. D., Smit, E. F., Cuppen, E. P. J. G., Wessels, L. F. A., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01448-w · Cited by 80
Wu, F., Yuan, Y. Z., & Wu, X. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202112609 · Cited by 74
LR-GNN: a graph neural network based on link representation for predicting molecular associations
Kang, C., Zhang, H., Liu, Z., Huang, S., & Yin, Y. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab513 · Cited by 83
An effector index to predict target genes at GWAS loci
Forgetta, V., Jiang, L., Vulpescu, N. A., Hogan, M. S., Chen, S., Morris, J. A., Grinek, S., Benner, C., Jang, D., Hoang, Q., et al. (2022) · Human Genetics · doi:10.1007/s00439-022-02434-z · Cited by 80
“Selecting positive control genes Positive control genes were de ned via two approaches: (1) clinician scientists manually inspected the Human Disease Ontology database(Schriml et al. 2019) for relevant ontological terms (Table S1), and the associated OMIM linkage information was used to obtain a list of genes associat…”
BackgroundMethodINPUT: An intelligent network pharmacology platform unique for traditional Chinese medicine
Li, X., Tang, Q., Meng, F., Du, P.-F., & Chen, W. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.03.006 · Cited by 79
“Considering that the targets in TCMSP were from Drugbank, all targets collected from TCMSP were retained without setting cutoffs [27].”
MethodThe genetic architecture of biological age in nine human organ systems
Wen, J., Tian, Y., Skampardoni, I., Yang, Z., Cui, Y., Anagnostakis, F., Mamourian, E., Zhao, B., Toga, A. W., Zalesky, A., et al. (2024) · Nature Aging · doi:10.1038/s43587-024-00662-8 · Cited by 84
Drug repurposing for Alzheimer’s disease and other neurodegenerative disorders
Cummings, J. L., Zhou, Y., Stone, A. V., Cammann, D., Tonegawa‐Kuji, R., Cacho, J. R. F., & Cheng, F. (2025) · Nature Communications · doi:10.1038/s41467-025-56690-4 · Cited by 88
“Withinthis network are targets for approved drugs that may be repurposed for thetreatmentofAD/NDDs. Drug-targetdatabases,suchasDrugBank 40 , are resources for network proximity analyses.”
Advancing precision oncology with AI-powered genomic analysis
Srivastava, R. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1591696 · Cited by 85
Patrick, M. T., Raja, K., Miller, K., Sotzen, J., Gudjonsson, J. E., Elder, J. T., & Tsoi, L. C. (2019) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2018.09.018 · Cited by 73
“The DrugBank database (Wishart et al., 2018) has recently received a major update, more than doubling its size.”
BackgroundHe, S., Zhang, C., Zhou, P., Zhang, X., Ye, T., Wang, R., Sun, G., & Sun, X. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20153633 · Cited by 79
“In recent years, artemisinin was found to also treat schizophrenic disorders for which the Phase III clinical trial has been completed [13].”
Background
Metadata
- Authors
- Wishart, D. S., Feunang, Y. D., Guo, A. C., Lo, E. J., Marcu, A., Grant, J. R., Sajed, T., Johnson, D., Li, C., Sayeeda, Z., Assempour, N., Iynkkaran, I., Liu, Y., Maciejewski, A., Gale, N., Wilson, A., Chin, L., Cummings, R., Le, D., Pon, A., Knox, C., & Wilson, M.
- Affiliations
- University of Alberta (CA)
- Corresponding author
- Wishart, David S
- Venue
- Nucleic Acids Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-11-08
- Volume
- 46
- Issue
- D1
- Pages
- D1074-D1082
- ISSN
- 0305-1048 (ISSN-L)
- 1362-4962
- PMC
- PMC5753335
- OpenAlex
- W2767891136
- Cited by
- 8,404
- References
- 22
- Citations by year
- 2026: 617 · 2025: 929 · 2024: 1327 · 2023: 1363 · 2022: 1322 · 2021: 1175 · 2020: 957 · 2019: 502 · 2018: 201 · 2017: 5
- FWCI
- 343.79
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Nucleic Acids Research (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Genome Canada
- Genome Alberta
- Health Canada
- Canadian Institutes of Health Research
- National Human Genome Research Institute
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Medicine › Health Informatics › Biomedical Text Mining and Ontologies
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- DrugBank, drug databases, drug-drug interactions, food-drug interactions, therapeutic target, drug mechanisms, drug indications, pharmacometabolomics, pharmacoproteomics, drug repurposing, clinical trials, investigational drugs
- MeSH terms
- Drug Interactions, User-Computer Interface, Food-Drug Interactions, Polymorphism, Single Nucleotide, Metabolome, Transcriptome, Databases, Pharmaceutical
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

